GSK said it welcomes Monday’s jury verdict in the Joiner case in Illinois state court finding in GSK‘s favour. “This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine,” the company said. “GSK will continue to vigorously defend itself against all other claims.” Prior to this verdict, the court rejected the Plaintiff’s ability to request punitive damages.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GlaxoSmithKline (GSK) Reveals Q4 Dividend: Here’s the Essential Information
- GSK says FDA expands Jemperli plus chemotherapy approval to new indication
- GSK price target lowered to 1,850 GBp from 1,950 GBp at Deutsche Bank
- 23andMe CEO Anne Wojcicki Moves to Take Company Private
- UK Stocks: GSK Shares Fall Despite Upgraded Outlook